25rhk044
10.3205/25rhk044
urn:nbn:de:0183-25rhk0449
Meeting Abstract
Evaluation of serum calprotectin as biomarker for the disease activity of recurrent pleuropericarditis and adults-onset Still’s disease
Weber
Weber
Sophie
S
University Hospital Heidelberg, Internal Medicine V, Rheumatology, Heidelberg
author
Kaudewitz
Kaudewitz
Dorothee
D
University Hospital Heidelberg, Internal Medicine V, Rheumatology, Heidelberg
author
Lorenz
Lorenz
Hanns-Martin
HM
University Hospital Heidelberg, Internal Medicine V, Rheumatology, Heidelberg
author
Blank
Blank
Norbert
N
University Hospital Heidelberg, Internal Medicine V, Rheumatology, Heidelberg
author
German Medical Science GMS Publishing House
Düsseldorf
610
20250917
engl
This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung).
M0627
044
Deutsche Gesellschaft für Rheumatologie
Deutsche Gesellschaft für Orthopädische Rheumatologie
53. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 39. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)
Deutscher Rheumatologiekongress 2025
Experimentelle & Translationale Rheumatologie
Wiesbaden
20250917
20250920
ET.26
TextIntroduction: Calprotectin (CLP, S100A8A9) is secreted by neutrophils and monocytes during systemic inflammation due to activation of innate immunity. We aim to evaluate serum CLP (sCLP) levels in patients with adult onset Still’s disease (AOSD) and idiopathic recurrent pleuropericarditis (PP) in active and inactive disease.Methods: This is a monocentric, retrospective trial with 130 adult patients (PP=60; AOSD=70) recruited between January 2021 and January 2024. The electronic medical records were evaluated and the correlation of biomarkers and clinical symptoms was analyzed. Statistical analyses comprised Mann-Whitney-U test, Chi-square test and ROC analyses.Results: AOSD patients had a median age of 40 years (range 8–85) and an observation period of 3.7 years (range 0.0–18.4). PP patients had a median age of 48 years (range 20–83) and an observation time of 2.2 years (range 0.0–13.9). Attack symptoms and medication showed distinct differences between the two groups. Approximately one third of patients had one to two attacks per year or even a chronic disease activity (≥3) while the other two-thirds had less than one attack per year in both groups.
C-reactive protein (CRP), serum amyloid A (SAA), sCLP and white blood cell count (WBC) correlated with the disease activity. The strongest correlation of biomarkers was found between CRP and SAA (AOSD r=0.823; PP r=0.769) and in relation to WBC the strongest correlation was detected between neutrophiles and sCLP (AOSD r=0.690; PP r=0.651).Conclusion: sCLP, along with CRP and SAA, indicate systemic inflammation and correlate with disease activity in patients with AOSD and PP.
0
0
0
0